IP Library Granted Patent US 12,194,035
Granted Patent B2
US 12,194,035 · App. 18/371,071 · Granted Jan 14, 2025

Methods for treating antipsychotic-induced weight gain

Inventors: Daniel R Deaver (Wilmington, NC); Mark Todtenkopf (Franklin, MA)
Assignee: Alkermes Pharma Ireland Limited
A61K31/485A61K9/20A61K31/439A61K31/496A61K31/519A61K31/551A61K31/5513A61K31/554C07D221/28C07D405/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,194,035
App. No.
18/371,071
Granted
Jan 14, 2025
Kind
B2
Abstract

The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.

Claims (29)

1. A method of treating bipolar disorder in a patient in need thereof, comprising orally administering, daily, to the patient a pharmaceutical composition comprising:

olanzapine;

10 mg of a compound having the structure:

 and

a pharmaceutically acceptable excipient.

2. The method according to claim 1 , wherein the compound is present in the pharmaceutical composition as a pharmaceutically acceptable salt.

3. The method of claim 1 , wherein the pharmaceutical composition is a tablet.

4. The method of claim 1 , wherein the pharmaceutical composition further comprises lactose.

5. The method of claim 1 , wherein the pharmaceutical composition further comprises magnesium stearate.

6. The method of claim 5 , wherein the pharmaceutical composition further comprises lactose.

7. The method of claim 1 , wherein the bipolar disorder is bipolar disorder I.

8. The method of claim 1 , wherein the bipolar disorder is bipolar disorder I with a mixed or manic episode.

9. A method of treating a manic or mixed episode associated with bipolar disorder I in a patient in need thereof, comprising orally administering, daily, to the patient a pharmaceutical composition comprising:

olanzapine;

10 mg of a compound, based on the free base weight, having the structure:

 and

a pharmaceutically acceptable excipient; wherein the compound is present in the pharmaceutical composition as a pharmaceutically acceptable salt.

10. The method of claim 9 , wherein the pharmaceutical composition is a tablet.

11. A method of treating bipolar disorder in patient in need thereof comprising:

orally administering daily to the patient 10 mg, based on the free base weight, a compound having the structure:

 and

administering to the patient, daily, an antipsychotic, wherein the antipsychotic is olanzapine.

12. The method of claim 11 , wherein administering the compound and administering the olanzapine occurs concurrently.

13. The method of claim 11 , wherein the bipolar disorder is bipolar disorder I.

14. The method of claim 11 , wherein the bipolar disorder is bipolar disorder I with a mixed or manic episode.

15. A method treating a manic or mixed episode associated with bipolar disorder I in a patient in need thereof comprising:

orally administering daily to the patient 10 mg, based on the free base weight, a compound having the structure:

 and

administering to the patient, daily, an antipsychotic, wherein the antipsychotic is olanzapine.

Assignments (3)
SECURITY INTEREST Recorded Feb 13, 2026
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 074858/0405 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (073213/0302) Recorded Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 074858/0429 →
SECURITY INTEREST Recorded Oct 23, 2025
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073213/0302 →